postmenopausal osteoporosis
Endocrinology · 2005–2007
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Mar 2007 | Recommended with restriction | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Mar 2007 | Recommended with restriction | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| ibandronic acid Treatment of established postmenopausal osteoporosis in patients with fracture due to minimal trauma. | Jul 2006 | Not recommended | no section in document |
| strontium ranelate Treatment of postmenopausal osteoporosis to reduce the risk of fracture in patients with established osteoporosis and a history of fragility fracture. | Jul 2005 | Recommended with restriction | no section in document |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| abaloparatideAbaloparatide for treating osteoporosis after menopause | TA991 | recommended restricted | 2024-08 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| calcitonin salmonMIACALCIC NASAL SPRAY 200IU calcitonin salmon (salcatonin) 2200IU/mL | 1991 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.